Company intelligence / Profile preview

Manage Mind

Ownership: Private
Development stage: Other

Overview

MindMed develops novel product candidates—primarily small molecules and psychedelic-based therapies—for treating brain health disorders such as generalized anxiety disorder and major depressive disorder. Its lead candidate MM120 ODT has entered Phase 3 trials for GAD. The company has expanded its pipeline with new formulations and indications.

Therapeutic areas: PsychiatryNeurology
Modalities: Small moleculePsychedelic-based therapyOther novel compounds targeting neurotransmitter pathways
Industry: Biotech

Beyond the preview

Go deeper on Manage Mind.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Manage Mind.

Explore the full profile